ArticleBritish journal of cancer2016

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

Yvette Drew et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.